Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Respir Med ; 211: 107194, 2023 05.
Article in English | MEDLINE | ID: mdl-36889518

ABSTRACT

PNX was described as an uncommon complication in COVID-19 patients but clinical risk predictors and the potential role in patient's outcome are still unclear. We assessed prevalence, risk predictors and mortality of PNX in hospitalized COVID- 19 with severe respiratory failure performing a retrospective observational analysis of 184 patients admitted to our COVID-19 Respiratory Unit in Vercelli from October 2020 to March 2021. We compared patients with and without PNX reporting prevalence, clinical and radiological features, comorbidities, and outcomes. Prevalence of PNX was 8.1% and mortality was >86% (13/15) significantly higher than in patients without PNX (56/169) (P < 0.001). PNX was more likely to occur in patients with a history of cognitive decline (HR: 31.18) who received non-invasive ventilation (NIV) (p < 0.0071) and with low P/F ratio (HR: 0.99, p = 0.004). Blood chemistry in the PNX subgroup compared to patients without PNX showed a significant increase in LDH (420 U/L vs 345 U/L, respectively p = 0.003), ferritin (1111 mg/dl vs 660 mg/dl, respectively p = 0.006) and decreased lymphocytes (HR: 4.440, p = 0.004). PNX may be associated with a worse prognosis in terms of mortality in COVID patients. Possible mechanisms may include the hyperinflammatory status associated with critical illness, the use of NIV, the severity of respiratory failure and cognitive impairment. We suggest, in selected patients showing low P/F ratio, cognitive impairment and metabolic cytokine storm, an early treatment of systemic inflammation in association with high-flow oxygen therapy as a safer alternative to NIV in order to avoid fatalities connected with PNX.


Subject(s)
COVID-19 , Noninvasive Ventilation , Pneumothorax , Respiratory Insufficiency , Humans , COVID-19/complications , COVID-19/epidemiology , Pneumothorax/epidemiology , Pneumothorax/etiology , Pneumothorax/therapy , Retrospective Studies , Respiratory Insufficiency/epidemiology , Respiratory Insufficiency/etiology , Respiratory Insufficiency/therapy , Noninvasive Ventilation/adverse effects , Risk Factors
4.
J Biol Regul Homeost Agents ; 25(3): 443-51, 2011.
Article in English | MEDLINE | ID: mdl-22023769

ABSTRACT

Sub-clinical cardiac dysfunction may be significantly associated with chronic obstructive pulmonary disease (COPD) with a different degree of severity. In a cross-sectional design we aimed to evaluate the frequency of left ventricular diastolic dysfunction (LVdd) and its correlation with lung function, pulmonary arterial pressure and systemic inflammation in a selected population of COPD at an early stage of their disease. Fifty-five COPD patients with no clinical signs of cardiovascular dysfunction were recruited and compared to 40 matched healthy controls. All the subjects underwent pulmonary function testing, doppler echocardiography, and interleukin-6 blood sampling. Presence of LVdd was defined according to the significant change in both the ratio between early and late diastolic transmitral flow velocity (E/A ratio), isovolumetric relaxation time (IVRT), and deceleration time (DT). The frequency of LVdd was higher in the COPD group (70.9 percent) compared to controls (27.5 percent). In these patients decreased E/A ratio, and prolonged IVRT and DT clearly pointed to left ventricular filling impairment, a condition we found to be especially severe in those patients suffering from lung static hyperinflation as expressed by inspiratory-to-total lung capacity ratio (IC/TLC) <0.25. Circulating levels of interleukin-6 were also higher among COPD patients compared to controls. The results of the present study suggest that subclinical left ventricular filling impairment is frequently found in COPD patients at the earlier stage of the disease even in the absence of any other cardiovascular dysfunction. Doppler echocardiography may help the early identification of LVdd in COPD patients.


Subject(s)
Interleukin-6/blood , Pulmonary Disease, Chronic Obstructive/blood , Pulmonary Disease, Chronic Obstructive/physiopathology , Ventricular Dysfunction, Left/blood , Ventricular Dysfunction, Left/physiopathology , Aged , Blood Flow Velocity , Cross-Sectional Studies , Echocardiography, Doppler , Female , Humans , Male , Middle Aged , Pulmonary Disease, Chronic Obstructive/complications , Pulmonary Disease, Chronic Obstructive/diagnostic imaging , Respiratory Function Tests , Ventricular Dysfunction, Left/complications , Ventricular Dysfunction, Left/diagnostic imaging
5.
Int J Immunopathol Pharmacol ; 24(4): 1119-24, 2011.
Article in English | MEDLINE | ID: mdl-22230422

ABSTRACT

Crohn's disease is an inflammatory bowel disease associated with a variety of systemic manifestations, including large and small airway involvement. The latter is most often a subclinical one, and requires expensive and invasive diagnostic approaches. Nitric oxide (NO) can be detected non-invasively in the exhaled air (eNO) and be considered as a surrogate marker of airway inflammation. eNO tested at multiple expiratory flows can be used to distinguish the alveolar concentration of NO (CalvNO) from the total amount of fractional eNO (FeNO). The aim of our study is to compare FeNO and concentration of alveolar nitric oxide (CalvNO) levels and to assess their relationship with pulmonary involvement in Crohn's patients differing in clinical stage and therapeutic regimens versus a group of healthy subjects. Thirty Crohn's patients not showing clinical evidence of pulmonary diseases and 21 non-smoking, non-atopic healthy controls were enrolled. FeNO (14.9±10.2 ppb vs 10.1±6.3 ppb, p=0.049) and CalvNO (4.4±2.2 ppb vs 2.6±1.9; p=0.006) values were found to be significantly higher in Crohn's patients than in healthy controls. Both FeNO and CalvNO correlated positively with the Crohn's Disease Activity Index. In conclusion, our results for FeNO and CalvNO confirm the presence of subclinical pulmonary involvement in Crohn's disease. eNO measurement may be of clinical value in the follow-up of Crohn's patients.


Subject(s)
Breath Tests , Crohn Disease/complications , Exhalation , Lung Diseases/diagnosis , Lung/metabolism , Nitric Oxide/metabolism , Adult , Asymptomatic Diseases , Biomarkers/metabolism , Case-Control Studies , Crohn Disease/diagnosis , Crohn Disease/drug therapy , Female , Gastrointestinal Agents/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Italy , Linear Models , Lung/physiopathology , Lung Diseases/etiology , Lung Diseases/metabolism , Lung Diseases/physiopathology , Male , Middle Aged , Predictive Value of Tests , Pulmonary Alveoli/metabolism , Severity of Illness Index
6.
J Biol Regul Homeost Agents ; 24(2): 123-30, 2010.
Article in English | MEDLINE | ID: mdl-20487625

ABSTRACT

The involvement of a number of potassium channels has been reported in respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), supporting the idea that potassium channel modulating agents may help control it. Experimental evidence and preclinical models suggest that ATP-dependent K(+) (K(ATP)) channel openers, big-conductance K(+) (BK(CA)) channel openers, and intermediate-conductance K(+) (IK(CA)) channel blockers may be the most effective agents for treating asthma and COPD. Modulation of potassium channels by these agents may produce beneficial effects such as bronchodilation, a reduction in airways hyperresponsiveness (AHR), a reduction in cough and mucus production and an inhibition in airway inflammation and remodelling. The aim of this paper is to investigate the role of K(+) channel modulation in the pathogenesis, progression and exacerbation of asthma and COPD, and to review the evidence suggesting that K(+) channel modulators may be a valuable treatment option for these respiratory diseases.


Subject(s)
Asthma/drug therapy , Potassium Channel Blockers/therapeutic use , Potassium Channels/physiology , Pulmonary Disease, Chronic Obstructive/drug therapy , Asthma/physiopathology , Bronchodilator Agents/therapeutic use , Humans , Intermediate-Conductance Calcium-Activated Potassium Channels/drug effects , Intermediate-Conductance Calcium-Activated Potassium Channels/physiology , KATP Channels/drug effects , KATP Channels/physiology , Large-Conductance Calcium-Activated Potassium Channels/drug effects , Large-Conductance Calcium-Activated Potassium Channels/physiology , Potassium Channel Blockers/pharmacology , Potassium Channels/drug effects , Pulmonary Disease, Chronic Obstructive/physiopathology
7.
Int J Immunopathol Pharmacol ; 23(4): 1195-202, 2010.
Article in English | MEDLINE | ID: mdl-21244768

ABSTRACT

Chronic plaque psoriasis is associated to an increased risk of cardiovascular events. The aim of our study is to test patients with psoriasis for common markers of acquired and inherited thrombophilia. A cross-sectional study on 172 patients with psoriasis and 198 controls was carried out. The plasma levels of coagulation protein C, coagulation protein S, homocysteine, folic acid, C-reactive protein (CRP) and fibrinogen as well as activated protein C resistance and antithrombin III activity, were measured. CRP and homocysteine levels were higher in patients with psoriasis than in controls (5.9 ± 7.1 vs 3.1 ± 2.4 mg/L, p=0.0003 and 16.3 ± 12.8 vs 10.4 ± 4.6 umol/L, p=0.0001; mean ± SD) whereas folic acid was lower in psoriatic patients compared to controls (4.3 ± 7.2 vs 12.6 ± 7.9 p=0.006). Levels of coagulation protein C, coagulation protein S, fibrinogen as well as activated protein C resistance, antithrombin III activity were within normal ranges both in cases and controls. In a multivariate regression analysis, psoriasis severity was an independent predictor of higher CRP. In conclusion, high levels of serum CRP and homocysteine were found in patients with psoriasis, related to the severity of the disease. These data suggest that the increased risk of thrombotic cardiovascular events observed in psoriasis patients should be ascribed to an acquired rather than inherited thrombophilic status.


Subject(s)
C-Reactive Protein/analysis , Psoriasis/blood , Thrombophilia/blood , Adult , Aged , Biomarkers , Chronic Disease , Cross-Sectional Studies , Female , Folic Acid Deficiency/complications , Humans , Hyperhomocysteinemia/etiology , Male , Middle Aged , Severity of Illness Index
8.
J Biol Regul Homeost Agents ; 23(4): 273-5, 2009.
Article in English | MEDLINE | ID: mdl-20003767

ABSTRACT

Venous complications of pacemaker implantation rarely cause immediate clinical problems. An 89-year-old man, without thrombophilia, 4 weeks after a pacemaker implantation experienced functional impotence of the left arm that appeared warm, reddened, oedematous and painful. Color Doppler Ultrasonography revealed a thrombosis of the axillary vein extended to the proximal third of the ulnar vein. In our opinion, upper extremity deep vein thrombosis (UEDVT) represents an important complication of post-surgical pacemaker implantation that should be suspected early, even without specific symptoms and thrombophilia.


Subject(s)
Pacemaker, Artificial , Venous Thrombosis/etiology , Aged, 80 and over , Axilla/blood supply , Axilla/diagnostic imaging , Axillary Vein/diagnostic imaging , Humans , Male , Ultrasonography, Doppler, Color/methods , Venous Thrombosis/diagnostic imaging
9.
J Biol Regul Homeost Agents ; 23(4): 269-72, 2009.
Article in English | MEDLINE | ID: mdl-20003766

ABSTRACT

Haemolytic anaemia following mitral valve replacement is uncommon, however in patients who suffer from some degree of perivalvular leak, severe and potentially fatal recurrent intravascular haemolysis can be an annoying problem. We report the cases of two patients with severe haemolytic anaemia observed some years after mitral valve replacement. In one of the two patients the presence of an association between a valvular leak after mitral valve replacement and a calcific atrial wall produced severe and recurrent haemolysis that required multiple blood transfusions. In the second patient the presence of a single valvular leak after mitral valve replacement induced an episode of haemolytic anaemia some years after the operation. These cases point out that in case of unexplained worsening anaemia, a transthoracic (TT) and transesophageal (TE) echocardiogram should be performed, and the possibility of atrial wall alterations in the producing of anaemia should be kept in consideration. In these cases reoperation resolved the recurrence of anemization.


Subject(s)
Anemia, Hemolytic/surgery , Hemolysis , Mitral Valve/metabolism , Aged , Anemia, Hemolytic/diagnostic imaging , Anemia, Hemolytic/etiology , Calcinosis/complications , Calcinosis/diagnostic imaging , Calcinosis/pathology , Calcinosis/surgery , Female , Heart Atria/diagnostic imaging , Heart Atria/pathology , Humans , Male , Mitral Valve/diagnostic imaging , Time Factors , Ultrasonography
10.
J Intern Med ; 265(3): 382-7, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19019191

ABSTRACT

OBJECTIVES: Although the likelihood of intermediate alpha-1-antitrypsin deficiency (PiMZ) patients developing chronic obstructive pulmonary disease (COPD) remains uncertain, several investigators have suggested that a lack of antiprotease inhibitor activity may favour the development of airway inflammation with subsequent pulmonary tissue damage. The levels of exhaled nitric oxide (FeNO) in PiMZ subjects are unknown and polymorphisms in nitric oxide synthase have been linked to lung disease susceptibility in subjects with alpha-1-antitrypsin (AAT) deficiency. This study was aimed at assessing FeNO levels in a group of PiMZ subjects and comparing it with the concentrations found amongst groups of COPD and control patients. DESIGN: A group of 31 PiMZ subjects, 31 COPD patients and 30 controls underwent pulmonary function tests, AAT assay and phenotyping, and FeNO measurement in an ambulatory setting. RESULTS: FeNO values observed in the group of PiMZ subjects (21.6 +/- 8.9 ppb) showed a significant increase compared with COPD (14.5 +/- 8.7 ppb; P < 0.01) and the control groups (9.1 +/- 2.9 ppb; P < 0.01). Within the PiMZ population, a significant, negative correlation was observed between plasma AAT levels and FeNO readings. CONCLUSIONS: Not only did PiMZ subjects show increased FeNO levels compared with COPD patients and controls; FeNO levels proved to be related to the reduced concentration of plasma AAT. Such findings seem to suggest the importance of FeNO measurements on PiMZ subjects for monitoring a possible progression of airway inflammation to obstructive lung disease as observed in some of these patients.


Subject(s)
Nitric Oxide/metabolism , Pulmonary Disease, Chronic Obstructive/metabolism , alpha 1-Antitrypsin Deficiency/metabolism , Adult , Aged , Breath Tests , Female , Forced Expiratory Volume , Humans , Male , Middle Aged , Pulmonary Disease, Chronic Obstructive/physiopathology , Vital Capacity , alpha 1-Antitrypsin Deficiency/physiopathology
11.
Eur Respir J ; 30(4): 769-81, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17906085

ABSTRACT

Bronchoalveolar lavage (BAL), induced sputum and exhaled breath markers (exhaled nitric oxide and exhaled breath condensate) can each provide biological insights into the pathogenesis of respiratory disorders. Some of their biomarkers are also employed in the clinical management of patients with various respiratory diseases. In the clinical context, however, defining normal values and cut-off points is crucial. The aim of the present review is to investigate to what extent the issue of defining normal values in healthy adults has been pursued for the biomarkers with clinical value. The current authors reviewed data from literature that specifically addressed the issue of normal values from healthy adults for the four methodologies. Most studies have been performed for BAL (n = 9), sputum (n = 3) and nitric oxide (n = 3). There are no published studies for breath condensate, none of whose markers yet has clinical value. In healthy adult nonsmokers the cut-off points (mean+2sd) for biomarkers with clinical value were as follows. BAL: 16.7% lymphocytes, 2.3% neutrophils and 1.9% eosinophils; sputum: 7.7 x 10(6).mL(-1) total cell count and 2.2% eosinophils; nitric oxide: 20.2 ppb. The methodologies differ concerning the quantity and characteristics of available reference data. Studies focusing on obtaining reference values from healthy individuals are still required, more evidently for the new, noninvasive methodologies.


Subject(s)
Bronchoalveolar Lavage , Exhalation , Inflammation/metabolism , Sputum/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers/metabolism , Breath Tests , Female , Humans , Male , Middle Aged , Nitric Oxide/metabolism , Reference Values
12.
Br J Dermatol ; 155(6): 1165-9, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17107384

ABSTRACT

BACKGROUND: Hyperhomocysteinaemia is a well-known risk factor for cardiovascular diseases. Patients with severe chronic plaque psoriasis have a higher risk of death due to arterial and/or venous thrombosis. OBJECTIVES: To investigate the relationship among plasma homocysteine and folate levels and severity of chronic plaque psoriasis in a selected cohort of patients with psoriasis without known risk factors for acquired hyperhomocysteinaemia. METHODS: We performed a case-control study in 40 patients with chronic plaque psoriasis and 30 age- and sex-matched healthy controls. Cases and controls were selected excluding individuals with conditions or diseases associated with acquired hyperhomocysteinaemia, and were also asked to stop alcohol and coffee consumption for 1 week before blood sampling. The plasma levels of homocysteine and folic acid were measured and were correlated with the severity of psoriasis (Psoriasis Area and Severity Index, PASI). RESULTS: Patients with psoriasis had plasma homocysteine levels higher than controls (mean +/- SD 16.0 +/- 5.6 vs. 10.4 +/- 4.7 micro mol L(-1); P < 0.001). Conversely, folic acid levels were lower in patients with psoriasis compared with controls (mean +/- SD 3.6 +/- 1.7 vs. 6.5 +/- 1.7 nmol L(-1); P < 0.001). Plasma homocysteine levels in patients with psoriasis correlated directly with disease severity (PASI) and inversely with folic acid levels. Plasma folic acid levels were inversely correlated with the PASI. No abnormalities of plasma vitamin B(6) and B(12) were found. CONCLUSIONS: Patients with psoriasis may have a tendency to hyperhomocysteinaemia, which may predispose to higher cardiovascular risk. Dietary modification of this risk factor appears relevant to the global management of patients with moderate to severe psoriasis.


Subject(s)
Folic Acid/blood , Homocysteine/blood , Hyperhomocysteinemia/diagnosis , Psoriasis/blood , Adolescent , Adult , Aged , Aged, 80 and over , Case-Control Studies , Chronic Disease , Cohort Studies , Female , Humans , Male , Middle Aged , Psoriasis/complications , Psoriasis/diagnosis
13.
Thorax ; 61(2): 129-33, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16284217

ABSTRACT

BACKGROUND: Severe alpha-1-antitrypsin deficiency (AATD), due to homozygosity for the protease inhibitor (Pi) Z allele, is a genetic risk factor for chronic obstructive pulmonary disease (COPD). In a previous study the sputum of severe AATD subjects with airflow obstruction showed a pattern of cellular inflammation similar to COPD patients. It is uncertain whether heterozygotes for the Z allele or intermediate deficiency (PiMZ) have an increased risk of developing COPD. METHODS: Sputum cell counts and the supernatant level of the neutrophil chemoattractant interleukin (IL)-8 were investigated by sputum induction in 10 non-smoker asymptomatic PiMZ subjects with normal pulmonary function, 10 patients with stable COPD, and 10 age matched normal subjects. Data are expressed as mean (SD). RESULTS: The mean (SD) number of neutrophils was significantly higher (p<0.01) in the sputum of PiMZ subjects (84.5 (22.2) x10(4)/ml) and patients with COPD (126.9 (18.8) x10(4)/ml) than in matched normal subjects (55.0 (8.7) x10(4)/ml). IL-8 levels were increased in PiMZ subjects (828.5 (490.6) ng/ml; median 1003.0 ng/ml; range 1260-100 ng/ml) and in COPD patients (882.5 (524.3) ng/ml; median 934.9 ng/ml; range 1506-258 mg/ml) compared with normal subjects (3.5 (0.5) ng/ml; median 3.5 ng/ml; range 4.5-2.5 ng/ml). There was a significant positive correlation between IL-8 supernatant concentration and neutrophil count in PiMZ subjects (p = 0.036; r = 0.66). An inverse correlation was observed between the percentage of neutrophils and forced expiratory volume in 1 second (% predicted) in patients with COPD (p = 0.04; r = -0.43). CONCLUSIONS: These findings indicate that PiMZ subjects without airflow obstruction may have an IL-8 related neutrophilic inflammation in the airways, similar to stable COPD patients, suggesting an increased risk of developing pulmonary changes.


Subject(s)
Bronchitis/metabolism , Interleukin-8/metabolism , Leukotriene B4/metabolism , alpha 1-Antitrypsin Deficiency/metabolism , Aged , Bronchitis/pathology , Carbon Monoxide/metabolism , Case-Control Studies , Female , Forced Expiratory Volume/physiology , Humans , Male , Middle Aged , Neutrophils/pathology , Sputum/cytology , Vital Capacity/physiology , alpha 1-Antitrypsin Deficiency/pathology , alpha 1-Antitrypsin Deficiency/physiopathology
15.
J Intern Med ; 253(3): 351-8, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12603503

ABSTRACT

BACKGROUND: It has been suggested that subjects with alpha-antitrypsin (AAT) deficiency, lacking a major antiprotease defence against airway inflammation, might be more susceptible of development of airway hyperresponsiveness (AHR). Moreover, lower AAT blood levels might also be able to influence the severity of AHR. OBJECTIVES: This study was aimed to investigate the prevalence of AHR in a large group of subjects with AAT deficiency included in the Italian Registry and to evaluate the relationship between AAT blood levels and the severity of AHR in this population. DESIGN: Cross-sectional controlled study. SETTING: Regional Reference Centre for AAT deficiency in Brescia, Italy. METHODS: A total of 114 subjects with AAT deficiency underwent pulmonary function tests. Eighty-six were eligible to perform a bronchial provocation test with methacholine (MCh) (baseline FEV1 > 60% predicted) to assess the provocative dose producing a 20% fall of FEV1 (PD20FEV1). Similar measurements were performed in a control group of 27 age-matched normal subjects. RESULTS: The prevalence of AHR (PD20FEV1 < 2000 microg MCh) was not different between AAT deficiency subjects and controls (16.3% and 11.1%, respectively; P = 0.66), and also amongst two subgroups of AAT deficiency subjects divided according to different protease inhibitor (Pi) phenotypes (PiMZ-MS, PiSZ-ZZ). Hyperresponsive subjects with AAT deficiency, however, showed a positive correlation between AAT blood levels and PD20FEV1 values (r = 0.71, P < 0.01). CONCLUSIONS: These findings indicate that AAT deficiency subjects did not exhibit a greater prevalence of airway hyperresponsiveness as compared with control subjects, but suggest that, in the subset of AAT deficiency subjects hyperresponsive to MCh, lower levels of AAT are associated with a higher severity of AHR.


Subject(s)
Bronchial Hyperreactivity/etiology , alpha 1-Antitrypsin Deficiency/complications , Adolescent , Adult , Aged , Bronchial Provocation Tests , Bronchoconstrictor Agents , Carbon Monoxide , Cross-Sectional Studies , Female , Forced Expiratory Volume/physiology , Humans , Male , Methacholine Chloride , Middle Aged , Vital Capacity/physiology
17.
Respir Med ; 95(6): 520-5, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11421511

ABSTRACT

There is no report of exhaled NO (eNO) in subjects with different phenotypes of alpha1-anti-trypsin (AAT) deficiency. Exhaled nitric oxide was evaluated by means of single-breath chemiluminescence analysis (fractional exhaled concentration at the plateau level [plFE(NO)]) in 40 patients with AAT deficiency. Patients were divided according to the protease inhibitor (Pi) phenotype: PiMZ/MS, n = 25; PiSZ n = 6; PiZZ, n = 9. Nineteen healthy subjects served as controls. Levels of eNO in PiZZ patients were also compared with those of subjects, without AAT deficiency (PiMM), matched for diagnosis, sex, age, smoking habit and forced expiratory volume in 1 sec (FEV1). In AAT deficiency subjects airway hyper-responsiveness to methacholine (PD20 FEV1) was also assessed. plFE(NO) was significantly lower in the PiZZ group (4.5+/-1.4 ppb) than in matched PiMM subjects (8.2+/-3.8 ppb), in healthy controls (9.3+/-2.8 ppb) and in patients of other phenotypes. Dynamic lung volumes and DL(CO) were significantly lower in PiZZ than in other AAT-deficient patients. Bronchial hyper-responsiveness was not different among AAT phenotypes. These results suggest that eNO may be significantly reduced in PiZZ as compared to healthy control subjects and to AAT subjects with other phenotypes, independent of the level of airway obstruction. Whether, at least potentially, eNO may be considered as an early marker of lung involvement in AAT deficiency must be confirmed with studies on larger number of subjects.


Subject(s)
Nitric Oxide/metabolism , alpha 1-Antitrypsin Deficiency/metabolism , Adult , Analysis of Variance , Breath Tests , Bronchial Provocation Tests , Case-Control Studies , Chi-Square Distribution , Female , Forced Expiratory Volume , Humans , Luminescent Measurements , Male , Methacholine Chloride , Phenotype , Respiratory Hypersensitivity/diagnosis , Respiratory Hypersensitivity/etiology , Statistics, Nonparametric , alpha 1-Antitrypsin Deficiency/complications , alpha 1-Antitrypsin Deficiency/genetics
18.
Recenti Prog Med ; 91(7-8): 352-61, 2000.
Article in Italian | MEDLINE | ID: mdl-10932919

ABSTRACT

In a longitudinal clinical study, two hundred subjects have been evaluated in order to identify alpha 1-antitrypsin deficiency patients. According to their serum alpha 1-antitrypsin levels, they have been divided into three groups: 25 patients with severe deficiency (with both pathological alleles--ZZ, SZ or Z and rare deficiency allele--and, if clinically suggested, to be treated with augmentation therapy), 92 patients with intermediate deficiency (with one pathological allele, to be followed up in order to evaluate the risk to develop deficiency related disease) and 63 healthy subjects (normal alleles MM). They performed lung function test (including cardiopulmonary exercise test and methacholine bronchial challenge) chest X-ray and high resolution computed tomography, blood tests. Severe deficiency patients also performed perfusional lung scan to detect early disorders of blood flow, evaluation of arterial blood gases and liver echotomography. Expiratory flow limitation, the prevalence of vascular disease, the amount of urine elastin products and correlations between the amount of nitric oxide exhaled and bronchial hyperresponsiveness have been also investigated. The study showed that in Brescia county the deficiency is more common than expected and that evaluation of liver and vessels might be as useful as lung function tests. In addition, beneficial effect on local system has been observed. The longitudinal study might permit to detect early organ damage and to eliminate additive risk factors.


Subject(s)
alpha 1-Antitrypsin Deficiency/epidemiology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Alleles , Female , Humans , Italy/epidemiology , Longitudinal Studies , Male , Middle Aged , Pedigree , Phenotype , Prospective Studies , Pulmonary Emphysema/diagnosis , Pulmonary Emphysema/etiology , Radiography, Thoracic , Risk Factors , Sex Factors , Tomography, X-Ray Computed , alpha 1-Antitrypsin/analysis , alpha 1-Antitrypsin Deficiency/diagnosis , alpha 1-Antitrypsin Deficiency/genetics
19.
Recenti Prog Med ; 90(3): 152-4, 1999 Mar.
Article in Italian | MEDLINE | ID: mdl-10228355

ABSTRACT

Paratracheal lymph-nodal metastases secondary of breast cancer aren't frequent in this kind of cancer. Here is described the case of a 76-years-old woman come to our note for ingravescent dyspnoea caused by metastatic adenopathy compression of the tracheal lumen. After excluding other treatments, a tracheal stent is put on. The obstruction gets better right away, the initial severe respiratory symptoms are improved and the ventilation is almost normal.


Subject(s)
Breast Neoplasms/complications , Carcinoma, Ductal, Breast/complications , Tracheal Stenosis/etiology , Aged , Breast Neoplasms/therapy , Carcinoma, Ductal, Breast/therapy , Combined Modality Therapy , Female , Humans , Lymphatic Metastasis , Stents , Time Factors , Tracheal Stenosis/diagnosis , Tracheal Stenosis/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...